DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer: a Multi-center Phase II Trial
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2018
At a glance
- Drugs DKN 01 (Primary) ; Atezolizumab; Paclitaxel
- Indications Adenocarcinoma; Biliary cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms DYNAMIC
- 29 Nov 2018 Status changed from planning to not yet recruiting.
- 12 Sep 2017 New trial record
- 08 Sep 2017 According to Leap Therapeutics media release, Leap Therapeutics will conduct this trial in collaboration with EORTC and Roche will supply atezolizumab to the EORTC for this study collaboration. Study is expected to begin enrolling patients in 2018.